Ocugen Inc (NASDAQ:OCGN) announced that immune response data following two doses of Covaxin from a third-party study were published on the preprint server, medRxiv.
- The data compared the immune memory response of 71 vaccinated and 73 naturally infected subjects with SARS-CoV-2, including variants of concern, for up to six months.
- The study found that Covaxin generated a robust immune memory against spike and nucleoprotein comparable to that following natural COVID-19 infection for the levels of antibodies, memory B cells, and memory CD4+ T cells.
- In the analysis, Covaxin generated T-cells against both spike and nucleocapsid proteins in nearly 85% of subjects that persisted for at least six months.
- The data support previous findings that the COVID-19 candidate can induce long-term memory.
- Ocugen is currently evaluating Covaxin against the Omicron variant and plans to share the data as soon as they are available.
- Covaxin is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research - National Institute of Virology.
- Price Action: OCGN shares are down 0.31% at $4.80 on the last check Wednesday.
